A new nanoparticle formulation successfully delivered oxytocin from the nose to the brain in mice, with reduced off-target exposure and confirmed behavioral effects.
93–116 nmDiameter of the optimized nanoparticles — small enough to penetrate nasal mucus and deliver oxytocin directly to the brain
What the researchers found
Researchers created PEGylated PLGA nanoparticles loaded with oxytocin (OT-NP-PEG) that successfully delivered the peptide from the nose directly to the brain in mice. The nanoparticles were 93–116 nm in diameter with sustained release (>42% at 24 hours, 58% at 72 hours) and showed greater diffusion through simulated nasal mucus than non-PEGylated versions.
Using radioactively labeled oxytocin ([14C] OT), the team demonstrated rapid brain uptake — particularly in the olfactory bulb and frontal cortex — with reduced accumulation in the blood and liver compared to free oxytocin. Mice treated with intranasal OT-NP-PEG showed increased self-grooming, confirming the oxytocin remained biologically active after delivery.
Why it matters
Oxytocin is being explored as a treatment for autism spectrum disorder, but nasal sprays deliver it inconsistently to the brain, with much of the peptide ending up in the bloodstream instead. This nanoparticle system could solve that problem by protecting oxytocin and routing it directly through the nose-to-brain pathway, potentially making oxytocin therapy more effective and reducing side effects.
The numbers in context
Particle size: 93–116 nm · Drug loading: 2.8–3.5% w/w · Release: >42% at 24h, 58% at 72h · Zeta potential: -21 to -33 mV · [14C] OT synthesis: 74% chemical yield, 53% radiochemical yield
How the study worked
Researchers used a Design of Experiments (DoE) statistical approach to optimize PLGA nanoparticle formulations loaded with oxytocin. They created both standard (OT-NP) and PEGylated (OT-NP-PEG) versions, characterizing particle size, stability, and release kinetics. They synthesized radioactively labeled [14C] oxytocin to track biodistribution after intranasal administration in mice, measuring uptake in the brain (olfactory bulb, frontal cortex), blood, and liver. Behavioral effects were assessed by measuring self-grooming frequency.
Who was studied
Mice (preclinical nanoparticle development and biodistribution study)
What this study cannot tell us
This is a preclinical mouse study — nose-to-brain delivery may differ significantly in humans due to anatomical differences. The behavioral endpoint (self-grooming) is a crude proxy for the social behavior effects sought in ASD treatment. No toxicity data or long-term safety assessment is reported. The transition from mice to human clinical use involves substantial formulation and regulatory hurdles.
How to read the evidence
This is a preclinical proof-of-concept study in mice. While the engineering and biodistribution data are rigorous, no human data exists yet, placing this at an early stage of translational development.
When this study was published
Published in 2026, this is cutting-edge nanotechnology research representing the latest developments in peptide brain delivery.
The bigger picture
Nose-to-brain delivery is one of the most active frontiers in peptide drug delivery, offering a way to bypass the blood-brain barrier entirely. This study demonstrates that rationally designed nanoparticles can successfully deliver a peptide to specific brain regions via the nasal route — a platform approach that could eventually be applied not just to oxytocin but to other neuropeptides for conditions like depression, PTSD, and neurodegeneration.
Questions still open
- Will the nose-to-brain delivery efficiency hold up in larger animals and eventually humans, where nasal anatomy is significantly different from mice?
- Can this nanoparticle platform be loaded with other therapeutic peptides for brain-targeted delivery?
- What are the long-term safety implications of repeated intranasal PLGA nanoparticle administration?
Common questions
How does nose-to-brain drug delivery work?
Why is oxytocin being studied for autism?
Read the original research
Design of Experiments (DoE)-Optimized Polymeric Oxytocin Nanoparticles for Enhanced Nose-to-Brain Delivery.
Small (Weinheim an der Bergstrasse, Germany), 22(8), e11603
Citation
Ahmad, Naveed; Han, Shunping; Utami, Rifka; Baker, Rafal; Helal, Dina; Li, Zhuoni; Tricklebank, Mark; Paloyelis, Yannis; Wang, Julie; Petrinovic, Marija M; Bansal, Sukhi; Al-Jamal, Khuloud T. (2026). Design of Experiments (DoE)-Optimized Polymeric Oxytocin Nanoparticles for Enhanced Nose-to-Brain Delivery.. Small (Weinheim an der Bergstrasse, Germany), 22(8), e11603. https://doi.org/10.1002/smll.202511603